Modulation of the RAAS as a Treatment for CKD

Dr. Harriet Syme


The renin-angiotensin-aldosterone system can be modified in numerous ways; including use of ACE-inhibitors, angiotensin receptor blockers, aldosterone antagonists and direct renin inhibitors. In this talk we will consider the purported benefits of modifying RAAS activation in patients with CKD and consider whether one class of drugs can really be expected to have benefit over any other.

Scroll to top